Table 3 Odds ratios and 95% confidence intervals for association individual and concurrent metabolic comorbidities and risks of recurrent metastatic disease using binominal logistic regression, N = 1081. Individual and concurrent metabolic variables were included in the multivariable analysis
Presence of metabolic comorbidities | With distant metastasis event N (%) | Without distant metastasis event N (%) | OR | 95%CI | P value |
|---|---|---|---|---|---|
DM or glucose intolerance | 90 (32%) | 197 (24.6%) | 1.442 | 1.071–1.943 | 0.016 |
Dyslipidemia | 78 (27.7%) | 221 (27.6%) | 1.007 | 0.746–1.364 | 0.966 |
Hypertension | 118 (41.9%) | 346 (43.25%) | 0.950 | 0.721–1.251 | 0.714 |
BMI risk | 66 (23.5%) | 186 (23.2%) | 1.013 | 0.735–1.397 | 0.935 |
DM/glucose intolerance + Dyslipidemia | 51 (18.1%) | 96 (12.0%) | 1.626 | 1.122–2.356 | 0.010 |
DM/glucose intolerance + Hypertension | 76 (27.0%) | 159 (19.9%) | 1.495 | 1.090–2.049 | 0.013 |
Dyslipidemia + Hypertension | 75 (26.7%) | 204 (25.5%) | 1.064 | 0.781–1.448 | 0.695 |
Dyslipidemia + BMI risk | 32 (11.4%) | 93 (11.6%) | 0.977 | 0.638–1.497 | 0.915 |
Hypertension + BMI risk | 45 (16.0%) | 125 (15.6%) | 1.030 | 0.710–1.493 | 0.877 |
DM/glucose intolerance + BMI risk | 23 (8.2%) | 59 (7.4%) | 1.120 | 0.678–1.850 | 0.678 |
≥3 metabolic comorbidities | 77 (27.4%) | 151 (18.9%) | 1.622 | 1.182–2.226 | 0.003 |
Any metabolic comorbidity | 146 (53.6%) | 460 (56.7%) | 0.875 | 0.664–1.152 | 0.341 |